Market Overview

Baird Analyst Says 'Don't Give Up' Yet On Gilead's Remdesivir

Baird Analyst Says 'Don't Give Up' Yet On Gilead's Remdesivir

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) fell Thursday afternoon in reaction to a disappointing report on an early readout for its remdesivir therapy, but investors should not "give up on this drug," Baird analyst Brian Skorney said on CNBC's "Closing Bell."

The preliminary and early data that was accidentally posted by the World Health Organization is one readout, and we need to see the full data, Skorney said. The full data set would detail if some of the sick patients had pre-existing conditions like diabetes or hypertension, he said. 

"If you adjust for these imbalances, maybe there is an effect here."

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

There are plenty of reasons for the public to look at the Chinese study with skepticism, "Closing Bell" host Sara Eisen said.

For example, data out of China by default may not be trustworthy, and it is not clear how early the drug was administered, she said. The study itself was terminated early due to lack of enrollment.

Skorney said he is "skeptical" that any sort of treatment can launch by the summer.

Unfortunately, remdesivir and hydroxychloroquine were the "best shots," but have since shown "significant reasons to be skeptical," he said. 

"Maybe one of them or both of them will show some ability to impact the disease to some extent but the silver bullet is not here."

Gilead shares were down 0.82% at $77.14 at the time of publication Friday. 

Related Link: Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone

Latest Ratings for GILD

Sep 2020RBC CapitalMaintainsOutperform
Sep 2020RBC CapitalMaintainsOutperform
Sep 2020Maxim GroupUpgradesHoldBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings


Related Articles (GILD)

View Comments and Join the Discussion!

Posted-In: Baird Brian Skorney Closing BellAnalyst Color Health Care Analyst Ratings Media General Best of Benzinga

Latest Ratings

TMENeedhamInitiates Coverage On17.0
IRJefferiesInitiates Coverage On42.0
JKSCredit SuisseUpgrades32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at